Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
J Formos Med Assoc. 2010 Aug;109(8):582-8. doi: 10.1016/S0929-6646(10)60095-2.
BACKGROUND/PURPOSE: Hepatic hydrothorax is an uncommon but important complication of liver cirrhosis. The optimal management of this condition remains unclear. This retrospective study evaluated the impact of therapeutic interventions on the outcome of patients with hepatic hydrothorax.
From August 1996 to March 2004, the medical charts of 52 patients with hepatic hydrothorax in the National Taiwan University Hospital were reviewed. Treatment methods, outcome of interventions, and survival time were described and analyzed.
At the time of diagnosis, four patients were Child-Pugh class A, 20 were class B, and 28 were class C. Twenty-eight (53.8%) patients received supportive care with thoracentesis for symptom relief. Among the other 24 patients, 16 (30.8%) were treated by chemical pleurodesis, 14 (26.9%) underwent surgical interventions, and six (11.5%) received both interventions. Intervention success, defined as resolution of hydrothorax for at least 3 months after the procedure, was achieved in 37.5% and 42.9% of patients who underwent chemical pleurodesis and surgery, respectively, with an overall success rate of 50%. The median survival of all patients was 8.6 months (range, 0.2-77.6 months). The median survival of patients with intervention success (22.5 months) was significantly longer than those with intervention failure (5.4 months) and supportive care (6.3 months). Multivariate analysis showed that only intervention success (p = 0.010, hazard ratio = 0.25) was an independent predictor of survival.
For patients with hepatic hydrothorax, aggressive medical or surgical intervention might improve survival over supportive management, especially when resolution of hydrothorax can be maintained for at least 3 months.
背景/目的:肝性胸水是肝硬化的一种罕见但重要的并发症。这种情况的最佳治疗方法仍不清楚。本回顾性研究评估了治疗干预对肝性胸水患者预后的影响。
1996 年 8 月至 2004 年 3 月,回顾了台湾大学医院 52 例肝性胸水患者的病历。描述和分析了治疗方法、干预结果和生存时间。
在诊断时,4 例患者为 Child-Pugh 分级 A,20 例为分级 B,28 例为分级 C。28 例(53.8%)患者接受胸腔穿刺以缓解症状的支持性治疗。在其他 24 例患者中,16 例(30.8%)接受化学胸膜固定术治疗,14 例(26.9%)接受手术干预,6 例(11.5%)接受两种干预措施。干预成功定义为治疗后至少 3 个月胸水缓解,接受化学胸膜固定术和手术治疗的患者分别有 37.5%和 42.9%的患者达到干预成功,总体成功率为 50%。所有患者的中位生存期为 8.6 个月(范围,0.2-77.6 个月)。干预成功患者(22.5 个月)的中位生存期明显长于干预失败患者(5.4 个月)和支持性治疗患者(6.3 个月)。多变量分析显示,只有干预成功(p=0.010,风险比=0.25)是生存的独立预测因素。
对于肝性胸水患者,积极的药物或手术干预可能比支持性治疗更能提高生存率,特别是在胸水缓解至少 3 个月的情况下。